Anecortave Acetate Risk-Reduction Trial (AART)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: AMD

In brief

The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.

Key facts

Study ID

NCT00333216

Run by

Alcon Research

People needed

24

Starts

2005-05-01

Expected to finish

2008-12-01

Last updated by the study team

2012-11-28

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Dry AMD in study eye, Wet AMD in non-study eye;
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Under 50;
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Contact Alcon Call Center for Trial Locations — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.